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Introduction
Implantation of the human embryo leads to invasion of
the endometrium by the extra-embryonic trophoblast
and colonization of the uterine arteries. This phenom-
enon enables the embryo to anchor itself onto the uter-
ine wall and thus maintenance of the pregnancy and
foetal growth via the placenta. For this semi-allogenic
graft to occur, the endometrium must first undergo a
number of structural and biochemical modifications
which are collectively referred to as decidualization.
Hence, an "implantation window" opens as a result of
the synchronization between embryonic development
and endometrial maturity. Lastly, trophoblast cells
transform the uterine vascular system – a change
which (together with the action of vasomotor factors)
enables adequate nourishment of the foetoplacental
unit. 
The physiopathology of human embryo
implantation 
The extravillous cytotrophoblasts (EVCTs) must
invade the decidua before being able to modify the
walls of the spiral arteries. However, unlike tumour
invasion or an inflammatory reaction, implantation is
an invasion that is controlled in time and space. Any
anomaly in invasion-promoting and invasion-limiting
factors may cause a pregnancy-related disease, such as
preeclampsia. In order to invade the decidua, the tro-
phoblast cells need both to recognize (via integrins and
cadherins) the various components of the membrane
and the extracellular matrix (ECM) and then break
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them down (with metalloproteases). To control this
invasion, the endometrium modifies the composition
of the ECM and secretes transforming growth factor
(TGF) and tissue metalloprotease inhibitors (TIMPs).
Moreover, the decidua is colonized by immune system
cells (NK cells, lymphocytes and macrophages) that
are responsible for the local production of cytokines
which promote or inhibit invasion by trophoblasts.
Endometrial decidualization
For the human embryo, implantation occurs when the
endometrial tissue and vascular configurations have
reached a receptive stage during the proliferative phase
and the beginning of the luteal phase, under the influ-
ence of sex hormones, growth factors, angiogenic and
vasomotor agents [1]. Thickening of the endometrium
depends on the secretion of oestrogens during the fol-
licular phase and is necessary but not sufficient for
embryo implantation. Ideally, a thickness of 8 to 12
mm between the two outermost endometrial leaflets is
required in the peri-ovulatory period. If endometrial
atrophy (<5 mm) is observed on the 10th day of the
cycle, adjuvant treatment can legitimately be pre-
scribed. The vaginal administration of micronized
oestradiol has been suggested by Tourgeman et al. [2],
since the endometrial thickness markedly increased
following the prescription of vaginally administered
oestradiol. Nitric oxide donors have also been tested,
with varying results: Battaglia et al. [3] did not
observe any effect of L-arginine on endometrial thick-
ness, whereas Sher and Fisch's self-controlled study
[4] of 4 female patients taking Viagra® showed signif-
icant increases in uterine vasodilation and endometrial
thickness. This result shows nicely that even though
the endometrium clearly depends on steroid hormones,
better vascularization can also improve defects in
endometrial thickness; this observation also explains
why some mucosae remain thin, even when exposed to
high oestradiol levels. 
Except during pregnancy, the ECM is composed of
collagens I, III, V and VI, fibronectin and periglandu-
lar tenascin deposits. During decidualization, the
endometrial stromal (decidual) cells produce a pericel-
lular matrix composed of collagen IV, laminin and
heparan sulphate. Substantial hydration of the stroma
occurs at the same time. These changes in the compo-
sition and hydration of the ECM make it easier for the
EVCTs to invade the decidua. The modified ECM also
establishes close contacts with the lymphoid cells
present in the decidua, thereby increasing the cellular
interactions between trophoblast and lymphoid cells.
Decidual hydration is revealed by ultrasonography
during the peri-ovulatory period, when one observes a
triple-line endometrium with hypoechogenicity (oede-
ma) on both sides of the central line of the uterine
space. After ovulation, luteal secretion of progesterone
will prompt the endometrium to become progressively
hypoechogenic as it goes towards the uterine cavity.
Fanchin et al. [5] studied this phenomenon by digitiz-
ing ultrasound scans and analyzing the endometrium's
grey-scale intensity. Six hypoechogenic groups were
defined: ≤30%, 31-40%, 41-50%, 51-60%, 61-70%
and >70%, with pregnancy rates of 59%, 57%, 35%,
20%, 16% and 11%, respectively (p<0.001). It is note-
worthy that on the day of the hCG, there were no inter-
group differences in terms of endometrial thickness or
oestradiol and progesterone levels. Fanchin thus con-
cluded that early luteal differentiation of the
endometrium (i.e. appearance of hyperechogenicity) is
detrimental to implantation and thus recommended
that embryos should be frozen (for transfer during a
more appropriate cycle) or that an antiprogesterone
drug (RU 486) should be used to delay progesterone-
driven transformation of the endometrium.
In cases of pre-ovulatory progesterone secretion,
the endometrium will display early maturation, which
is unfavourable for embryo implantation. Hence, in
collaboration with Professor Philippe Bouchard, we
studied 15 women in an IVF programme (with a long
agonist protocol) and who presented an abnormally
high progesterone levels (>2 ng/ml) at the end of the
follicular phase. This anomaly has been linked to a
mutation in the gene for 21-hydroxylase (21-OHase),
an enzyme involved in cortisol synthesis. A 21-OHase
deficiency induces an increase in the syntheses of
progesterone and 17-hydroxyprogesterone (17-OH-P)
by the adrenal glands. The 21-OHase blockade was
confirmed by assaying for 17-OH-P at baseline and
after synacthen injection (ACTH). Endometrial biopsy
samples from these women showed that endometrial
maturation was occurring too early (according to the
criteria of Noyes et al. [6]), as confirmed by the pres-
ence of glandular and stromal progesterone receptors
at the end of the follicular phase. Hydrocortisone treat-
ment enabled these women to achieve follicular-phase
progesterone rates below 1 ng/ml, re-establish normal
endometrial maturation and obtain pregnancies.
This endometrial maturation is also associated with
growth of the spiral arteries (branches of the uterine
arteries), which will then carry maternal blood toward
the intervillous spaces of the placenta. The growth rate
and structure of the spiral arteries depend on ovarian
hormonal secretions. Under the influence of oestro-
gens, the spiral arteries' diameter increases as they
grow longer and become progressively twisted. This
endothelial proliferation continues during the luteal
phase and the first few weeks of gestation. Growth fac-
tors also play a role in neoangiogenesis: levels of
fibroblast growth factor b (FGFb, a powerful angio-
genic factor) are increased by oestradiol and inhibited
by progesterone, vascular endothelial growth factor
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(VEGF, stimulated by oestrogens and hypoxia) is
mitogenic for endothelial cells and increases vascular
permeability, whereas platelet-derived growth factor
(PDGF) contributes to angiogenesis and to the growth
of smooth muscle cells. This neoangiogenesis can be
disrupted by disease states that are associated with
microangiopathy, such as insulin-dependent or gesta-
tional diabetes and chronic or gestational hypertension
after a kidney transplant.
Endometrium-embryo interactions
The embryo (morula) arrives in the uterine cavity
between 132 and 144 hours after fecundation. As soon
as the trophectoderm is formed, it expresses LIF recep-
tors; LIF is produced by the endometrium in the peri-
implantation period and is involved in differentiation
of the cytotrophoblast into the syncytiotrophoblast,
hCG secretion and the expression of cell surface inte-
grins. The blastocyst secretes several factors, including
hCG (stimulating the ovarian production of proges-
terone) and IL-1. Receptors for the latter are present at
the surface of endometrial epithelial cells during the
luteal phase and their activation leads to secretion of
LIF; this clearly shows that a mother-embryo dialogue
(driven by growth factors and cytokines) becomes
established well before contact between the embryo
and the endometrium [7]. 
Contact between the blastocytic trophoblast and the
endometrium is necessarily preceded by blastocyst
hatching, which is under the influence of the endome-
trial lysine production resulting from decidualisation.
If hatching does not occur spontaneously, we can per-
form it mechanically or chemically as part of an IVF
procedure.
Adhesion by EVCTs involves plasma membrane
receptors (integrins and cadherins) that enable the
cells to identify and then bind to ECM components
(collagen IV, laminin, proteoglycans, heparan sul-
phate, entactin and fibronectin). Integrins are het-
erodimeric glycoproteins with 2 subunits (α and β),
the combination of which forms many different inte-
grins that bind to various ECM components [8]. The
integrin subunit β3 appears at day 20 of the cycle and
coexists with subunits α1, α4 and αv. Subunit αvβ3
is thus an excellent marker for the implantation win-
dow. Loop interactions enable anchorage of the
embryo: trophoblast αvβ3 recognizes endometrial
osteopontin and endometrial αvβ3 interacts with the
vitronectin and fibronectin expressed by the tro-
phoblast (Fig. 1). Lessey et al. [9] has estimated that
approximately two thirds of women with idiopathic
infertility and all of those with delayed endometrial
maturation have an αvβ3 deficiency. When these
women were treated with progesterone, histological
findings for 16 of 23 patients returned to normal, with
11 out of 16 having an adequate β3 level and 5 out of
16 β3-deficient women also displaying endometriosis.
Creus et al. [10] performed two endometrial biopsies
for each of 55 infertile women, one in the middle of the
luteal phase (6 to 8 days after ovulation) and the other
at the end (10-12 days). Nine patients had a defective,
out-of-phase endometrium (i.e. a defective luteal
phase, DLP) at the first biopsy but none were out of
phase at the second biopsy. The only integrin-related
difference between the DLP and the normal luteal
phase (NLP) was that only the NLP group expressed
integrin αvβ3 in the first biopsy. We have studied plas-
ma progesterone levels during these defective luteal
phases (Merviel P. and Zorn JR, unpublished). A
defective luteal phase (DLP) is characterized by a nor-
mal duration of elevated basal temperature (>11 days),
a normal plasma progesterone level at day 22 (>5
ng/ml) and an abnormal endometrial biopsy at day 22
(with a delay in endometrial maturation of approxi-
mately 2 days). We initiated hormone assays at the
time of the LH surge initiating rise (LH-SIR) when LH
plasma levels reach 180% of the baseline value. We
observed that progesterone secretion was delayed from
the peri-ovulatory period onwards (until 120 hours
after the LH-SIR). When the plasma progesterone
curves in the DLP and NLP were compared, a lag of
approximately two days was observed. Early proges-
terone supplementation resulted in a normal endome-
trial biopsy at day 22. More generally, there was a
clear αvβ3 deficiency not only in patients with
endometriosis or idiopathic infertility but also in those
with hydrosalpinx, early miscarriage or polycystic
ovary syndrome.
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Fig. 1. Trophectoderm-Endometrium integrin interactions during
implantation. Ln – laminin; Vn – vitronectin; Fn – fibronectin
Trophoblast invasion of the decidua
A "switch" modifies the integrin profile as the cytotro-
phoblast cells change from a proliferative state (at the
base of anchoring villi) to an interstitial position (in the
deepest portion of the decidua and spiral arteries) [11].
Thus, proliferative EVCTs first express only integrin
α6β4 (a receptor for laminin, a component of the base-
ment membrane) and then acquire the ability to
express integrin α5β1 (a fibronectin receptor) as they
become invasive and migrate. Once the cytotro-
phoblast cells have become interstitial and perivascu-
lar, integrin α1β1 (laminin and type I/IV collagen
receptors) also appear.
Since the ECM is organized into a three-dimen-
sional network that prevents passive cell migration,
adhesion of trophoblast cells to ECM components is
necessary but not sufficient for invasion. Accordingly,
the trophoblast cell must be able to proteolyse the ECM
components. Matrix metalloproteases (MMPs) are
endoproteinases that require the presence of Ca++ and
Zn++ ions and comprise 13 members in three families:
collagenases (MMPs 1, 8, 13), which break down type I
and III collagens; gelatinases A (MMP 2) and B (MMP
9), which break down gelatin, collagen IV and elastin;
and the stromelysins (MMP 3, 7, 10 and 11), which have
a broader spectrum. These enzymes are regulated by
their level of activation (most are secreted as inactive
zymogens) and the presence of TIMPs (secreted by the
decidua) which block the enzyme's active site. The tro-
phoblast cells secrete a number of MMPs during the
first trimester, including MMP 9, which plays a primor-
dial role in the invasion. Expression of TIMP 1 (which
is highest at term) balances MMP 9 activity and thereby
controls the invasiveness of the trophoblast. Further-
more, integrins can modulate MMP expression.
Tissue growth factor β (TGF β) is expressed at the
foetomaternal interface from the first trimester through
to term and inhibits trophoblast proliferation and inva-
sion; TGF β1 and TGF β2 are essentially expressed by
the villi and the decidua, respectively. Tissue growth fac-
tor β1 promotes formation of ECM (collagen and
fibronectin, in particular), induces TIMP 1 expression
and reduces EVCT migration by overexpressing α5β1.
This overexpression makes the EVCTs adhere more
strongly to the ECM and activates the differentiation of
the cytotrophoblast into a non-invasive syncytiotro-
phoblast.
Invasion of the uterine spiral arteries by the
extra-villous cytotrophoblast
The establishment of the uteroplacental vascular sys-
tem begins with the invasion of the maternal decidua
by EVCTs. Two successive, interdependent phenomena
are needed to accomplish the complete transformation
of the uterine spiral arteries by trophoblast cells [12].
The first vascular invasion by the
cytotrophoblast 
During the first trimester (from 5 to 8 weeks, approxi-
mately), the EVCTs sheath the outer wall of the decid-
ual capillaries and the intra-endometrial branches of
the uterine spiral arteries and thereby create a tro-
phoblastic shell around these vessels. The trophoblast
cells move from the exterior towards the inner capil-
lary walls, where they become organized into loose but
interlinked clusters within the trophoblastic shell.
These intravascular plugs obstruct almost all of the
decidual capillaries but act as a filter rather than a bar-
rier; the permeability of these plugs enables plasma
(and some maternal red blood cells) to diffuse towards
pools of blood that have formed as a result of vascular
invasion and which correspond to the future intervil-
lous spaces [13]. 
This anatomical phenomenon results in an increase
in oxygen partial pressure (PO2) upstream of the plugs
and a decrease downstream of them. The higher
upstream PO2 diminishes lipid peroxidation in the
endothelial cells of the intramyometrial spiral arteries,
which in turn translates into an increase in levels of
prostacyclin (the so-called prostaglandin I2, PGI2), a
decrease in thromboxane A2 (TXA2) and a correspon-
ding increase in local vasodilatation. The increase in
PO2 also decreases production of the vasoconstrictor
endothelin 1 (ET-1). Downstream of these plugs, the
lower PO2 helps ensure the best possible environment
for embryonic organogenesis. Conversely, the high
pressure upstream of the plugs increases ET-induced
nitric oxide (NO) release in the myometrial spiral
arteries and thus helps to further increase local vasodi-
latation [14,15]. The placental PO2 (while lower than
endometrial PO2 during the first trimester) increases
progressively between 8 and 12 weeks. Moreover,
since first-trimester embryos lack defence systems
against oxygen free radicals, this low PO2 level pro-
tects their tissues against the harmful effects of oxygen
[16]. Lastly, embryos at this term contain embryonic
haemoglobin, which has a greater affinity for oxygen
in low partial pressure conditions (such as those
encountered in plasma).
The existence of plugs in the endometrial capillar-
ies should theoretically be accompanied by a stacking
of maternal red blood cells upstream and the appear-
ance of extensive thrombi. However, this is not
observed in vivo because the local factors that regulate
local haemostasis (thrombomodulin, tissue factor and
plasminogen activator) work together to (i) ensure that
blood flows through the uterine spiral arteries and (ii)
prevent extravasation following EVCT invasion.
Thrombomodulin (TM) is secreted by the endothelial
cells and activates protein C, which has a proteolytic
activity and inhibits the formation of blood clots. Via
its anticoagulant action, TM prevents the formation of
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intravascular thromboses. Pro-coagulant tissue factor
(TF) is a located on the membranes of the endometrial
stromal cells (during the secretory phase) and the
perivascular decidual cells. Secretion of TF can be
secreted by progesterone and contributes to the
perivascular, endometrial haemostasis required after
EVCT vascular invasion by synthesizing thrombin
(which transforms fibrinogen into fibrin). At the same
time, fibrinolysis in the decidua is inhibited via activa-
tion of plasminogen activator inhibitor type 1 (PAI-1)
and a decrease in tissue-type and urokinase-type plas-
minogen activators (tPA, uPA).
The plugs in the decidual capillaries provide
haemodynamic protection for the embryo by prevent-
ing high vascular pressure in the blood lakes. The
increased sinuosity of the spiral arteries at the begin-
ning of pregnancy (which has a damper effect on
maternal blood flow) and the extraembryonic coelom
also play a role in this protection. In cases of sponta-
neous abortions, it is frequently observed that in the
absence of intravascular plugs, the mother's blood has
flooded the intervillous lakes [17]. At the beginning of
pregnancy, the embryo evacuates its waste towards
the yolk sac. There is no embryonic circulation and
the pressure in the villous capillaries is lower than in
the blood lakes. The transfer of nutrients and oxygen
therefore occurs solely from the mother to the
embryo. At 4-5 weeks, foetal heart activity begins and
pressure in the villous capillaries increases thence-
forth, enabling transfers from the embryo to the moth-
er. The plugs in the maternal vessels protect these
embryonic-maternal exchanges, since a substantial
increase in the blood lake pressure would stop the
transfers, cause collapse of the villous vessels and
prevent the embryo from thriving. This would lead to
cessation of embryonic-placental circulation and thus
death of the embryo [18].
The second vascular invasion by the
cytotrophoblast
Plugs in the intra-endometrial arteries can be observed
from 5 weeks onwards and then progressively disag-
gregate from week 8 through to week 13. The second
and final trophoblast invasion of the intramyometrial
spiral arteries thus occurs between 13 weeks and 18
weeks. Since these are continuous phenomena,
intramyometrial vascular invasion can sometimes be
observed before 13 weeks. A proportion of the tro-
phoblast cells in the plugs can move backwards to col-
onize the surface of the inner wall of the intramyome-
trial spiral arteries and then penetrate deep into the
vascular tissue [19]. This intraparietal encroachment
causes the endothelial cells and smooth muscle cells of
the tunica media and the internal elastic layer to disap-
pear progressively [20]. The latter is replaced by a fib-
rin deposit that deprives the vessels of their contractil-
ity. The trophoblast cells progressively develop an
endothelial phenotype because of a switch from E- to
VE-cadherin and the acquisition of endothelial cell
molecules (such as VCAM-1 and PECAM-1) [21].
Decreased resistance in the uterine arteries triggers the
continuous blood flow through the intervillous spaces
that is required for foetal growth during the second and
third trimesters. Intervillous blood flow increases at
around 10-12 weeks of gestation and results in expo-
sure of the trophoblast to higher oxygen tensions [22]. 
These anatomical and haemodynamic processes
can be visualized in a Doppler study by the disappear-
ance of the uterine artery notch, increased diastolic
flow through these arteries and the blood flow that
appears in the intervillous spaces. This progressive
replacement of the collagen and elastin framework and
the transformation of the intramyometrial spiral arter-
ies is generally complete at 18 weeks but sometimes
requires several additional weeks (it is not unusual for
notches to disappear on Doppler ultrasound examina-
tions between week 22 and week 26). During this peri-
od, the foetus acquires foetal haemoglobin (HbF), the
oxygen-uptake capacities of which match the greater
needs for foetal growth.
Hence, there is a clear paternal role in the phenom-
enon of implantation (as in molar pregnancies, where
paternal uniparental disomy is observed). In order to
assess the influence of the decidual environment on
placentation and trophoblast differentiation, we have
collaborated with Professor J.M. Foidard to compare
ectopic (tubal) pregnancies occurring in the absence of
differentiated decidua with gestational age-matched
normal pregnancies [23]. Differentiation of EVCTs in
anchoring villi from both uterine and ectopic pregnan-
cies showed a comparable switch from a proliferative
to an invasive phenotype. Whereas α6β4 integrin, E-
cadherin, EGF receptor and connexin 40 were
immunolocalized in the proximal proliferative cells of
the columns, α5β1, α1β1, C erb B2 and connexin 32
were expressed by invasive cytotrophoblasts. This
immunohistochemical characterization of trophoblast
differentiation suggests that the maternal decidua does
not seem to be required for acquisition of the invasive
phenotype during the first trimester of pregnancy.
Maternal red blood cells accumulate upstream of
the plug and can thus form a clot in hypercoagulant
states, such as when thrombophilia is present [24].
This clot blocks the passage of plasma ultrafiltrate and
leads to embryonic failure. If a clot has formed
upstream of the plugs, it will persist after plug disag-
gregation – leading to permanent blockage of the pla-
cental vascular bed and prevention of the trophoblasts'
counter-current arterial migration. The absence of this
second trophoblast invasion leads to pregnancy-asso-
ciated vascular pathologies, such as preeclampsia
S29Physiopathology of human embryonic implantation: clinical incidences
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(5): S29 (S25-S34) 
10.2478/v10042-009-0058-3
[25,26]. The occurrence of recurrent miscarriages is
thus associated with a higher incidence of pregnancy-
associated vascular complications.
Vasomotor factors
Pregnancy is associated with a decrease in blood pres-
sure, a drop in systemic and uterine vascular resistance
and a reduced response to various vasopressor (vaso-
constrictive) agents. The tone of the uteroplacental
vessels is regulated by a variety of factors. Schemati-
cally, uterine vascular tone is mainly regulated by a
vasoconstrictor system (endothelin/enkephalinase) and
an opposing vasodilator system (nitric oxide/guanylate
cyclase). These agents are involved in the placental
regulation of vascular flow and set up a local balance
that enables adequate blood intake [27]. Certain dis-
eases (such as the vascular complications of hyperten-
sion) may be due to deregulation of these systems. It is
now generally agreed that endothelial cells and
endocrine & nervous system factors are involved in the
regulation of vasomotor tone and also prevent platelet
aggregation.
Endothelin (ET) is one of the most powerful vaso-
constrictive factors in the foetal-placental circulation.
It is a 21-amino-acid peptide that exists in three iso-
forms (ET-1, ET-2 and ET-3) and which targets the spi-
ral artery endothelial cells. Endothelin is broken down
by the enzyme enkephalinase, the production of which
is induced by progesterone. Thus, in the middle of the
luteal phase (at the progesterone peak), the ET to
enkephalinase ratio favours ET breakdown and there-
fore contributes to the absence of vasoconstriction of
the implantation site vessels. Moreover, the hypothesis
in which ET-1 is involved in disorders such as
intrauterine growth retardation and preeclampsia
seems to be confirmed by the elevated concentration of
immunoreactive ET in both the umbilical vessels and
the maternal blood in such cases and increased ET-1
gene expression in the placental villi in preeclampsia
[28,29].
When intact, endothelium produces a highly labile
vasodilator product – nitric oxide (NO) – and triggers
up-regulation of the local blood flow [15,30]. This gas
(which can diffuse freely through cell membranes)
penetrates the smooth muscle cells surrounding the
vessels and relaxes them by activating cGMP [26].
Pregnancy is associated with increased NO produc-
tion. Moncada et al. [31] showed that administration of
inhibitors of NO synthase or guanylate cyclase ampli-
fies the vasoconstriction observed with ET-1 and
TXA2.
Oestrogens (in particular oestradiol) have both
direct (i.e. non-genomic) and indirect (via protein syn-
thesis) vasodilatory effects on the uterine arteries (via
ET-1, NO and prostaglandins in the latter case) [32]. In
fact, oestrogens facilitate Ca++ entry into the endothe-
lial cell, which leads to NO synthesis via stimulation
of NO synthase and then to a relaxant effect on the
muscle via cGMP. Endothelin-1 synthesis is also
reduced by oestradiol. Progesterone modulates the
effect of vasopressin on the uterine arteries in a dose-
dependent manner mechanism: progesterone is a
vasodilator alone or combined with micromolar
oestradiol but is a vasoconstrictor at lower doses (1 to
10 nM) [32]. 
Other factors are also involved in the regulation of
vascular tone. Prostaglandins are auto/paracrine mole-
cules derived from the metabolism of arachidonic acid
and are thus either vasoconstrictive (PGF2α, TXA2) via
an increase in intracellular Ca++ and protein kinase C
(PKC) stimulation or vasodilatory (PGE2, PGD2,
PGI2) via a mechanism mediated by adenylate cyclase
and cAMP formation. During a normal pregnancy, the
ratio of prostacyclin to thromboxan increases progres-
sively throughout the pregnancy. Prostacyclin (PGI2)
is produced by vascular ET and trophoblast cells and
has vasodilatory effects (by relaxing vessels contract-
ed by angiotensin II) and muscle-relaxing and anti-
aggregating effects. Thromboxan A2 is synthesized by
the platelets and is a powerful vasoconstrictor which
also promotes platelet aggregation and uterine contrac-
tility. During a normal pregnancy, the intravascular
plugs formed by the EVCTs at the junction between
the spiral arteries and the intervillous spaces inhibit
membrane lipid peroxidation and diminish TXA2 lev-
els [33]. Accordingly, the predominance of PGI2's
action compared with that of TXA2 (i.e. an increase in
the PGI2/TXA2ratio) causes vasodilation and decreas-
es vascular resistance. The absence of these plugs in
preeclampsia (caused by a defect in the EVCT vascu-
lar invasion) reduces the PGI2/TXA2 ratio (by decreas-
ing PGI2 synthesis and increasing that of TXA2) and
leads to (i) augmentation in the sensitivity of maternal
vessels to angiotensin II, (ii) the absence of vasodi-
latation and (iii) the formation of localized
microthromboses. Moreover, prostaglandin's vasomo-
tor action can be modified by vascular alterations (fib-
rin deposits, endothelial lesions, etc.). A number of
studies have revealed the presence of these vascular
lesions in the placentas of 57% of women with intra-
uterine growth retardation (IUGR) and 74% of women
with hypertension. The lesions thus further reduce per-
fusion of the intervillous spaces.
During pregnancy, adrenocorticotropic hormone
(ACTH) is present in both the maternal and foetal cir-
culations [34]. It is a more powerful vasodilator (by a
factor of 187) than PGI2. In pregnancies complicated
by preeclampsia or IUGR, ACTH levels in the umbili-
cal artery are elevated in response to stress and the
hypoxemia that results from diminished blood flow.
Corticotropin releasing factor (CRF) is a powerful
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vasodilator (50 times PGI2) whose levels are higher
during pregnancies complicated by hypertension or
IUGR [34] as a response to diminished placental vas-
cular flow. However, endothelial alterations reduce
corticotropins vasodilatory activity.
The vasomotor peptides, such as vaso-intestinal
peptide (VIP), substance P (SP) and calcitonin gene-
related peptide (CGRP), synthesized by nerve fibres
near the uterine vessels also help regulate uteroplacen-
tal blood flow. Vaso-intestinal peptide and SP exert a
vasodilatory action on uterine vessels contracted by
vasopressin (with no effect on basal parietal tension)
and on villous vessels contracted by PGF2α [14]. In
humans, CGRP appears to be a growth factor for the
endothelial cells of the umbilical vein and an angio-
genic factor under ischaemic conditions [35]. Experi-
ments in rats show that CGRP may inhibit the hyper-
tension induced by administration of L-NAME (an
analogue of L-arginine that inhibits NOS) and may
reduce the foetal mortality associated with hyperten-
sive syndromes. However, CGRP does not improve
birth weight [36]; this is explained by the fact that
CGRP does not cross the placenta and only corrects
the NO deficit on the mother's side.
The beneficial effects of calcium supplementation
in reducing the risk of preeclampsia suggests that cal-
cium plays a role in this condition [37,38]. Compared
with a normal pregnancy, the platelets of a woman
with preeclampsia have a higher intracellular calcium
level, which is probably related to an increase in volt-
age-dependent calcium channel activity. Pregnancy
and elevated blood oestradiol levels affect these chan-
nels and reduce the concentration of intracellular cal-
cium.
The uterine immune balance 
In theory, an implanting embryo is a potential target
for various types of immune attacks: standard cell-
mediated lysis, NK cell lysis and lysis by cytotoxic
antibodies associated with complement. During preg-
nancy, the embryo is protected from these dangers by
several factors: its own early antigenicity, secretion of
cytokines and local immunosuppressors, intrinsic
resistance to cell lysis and the MCP-DAF system. Two
phases occur: an initial maternal immunological reac-
tion against the allograft, followed by the development
of allogenic tolerance.
The trophoblast cells in contact with maternal
blood do not possess class I or II HLA antigens. HLA
G is expressed solely in the EVCTs at the foetal-mater-
nal interface (where no other class I or II antigens are
found). This particular pattern of HLA G expression
plays a role in tolerance of the semi-allogenic graft con-
stituted by pregnancy; the NK response is inhibited
because the trophoblast cells are disguised as self cells. 
Cytokines may be secreted by leukocytes having
infiltrated into the decidua or may be synthesized by
endometrial or trophoblast cells.
Cytokines involved in the inflammatory reaction:
IL-1 is detected in the decidua and IL-1 receptors are
found on endometrial epithelial cells. The embryo also
secretes IL-1, suggesting that it controls its own devel-
opment via interferon (IFN) – a trophic factor for the
trophoblast and for which the embryo has receptors.
Interleukin 1 appears to stimulate the production of
IFN, IL-6 and E2 prostaglandin (PGE2) and enable the
expression of class II HLA antigens (HLA-DR) in the
uterus.
Cytokines involved in trophoblast development:
CSF 1, GM-CSF and G-CSF are secreted in large
quantities in the decidua and cognate receptors are
expressed by the early trophoblast. CSF 1 favours the
growth of the trophoblast, whereas GM-CSF plays a
direct role in the trophoblast's attachment and growth
and in embryonic survival. The latter factor is secreted
by CD 56+ large granular lymphocytes (LGLs) present
in the decidua. The G-CSF receptors required for
implantation are found in the trophoblast and the
decidua.
Immunosuppressive cytokines: IL-6 inhibits
expression of IL-2 receptors, which would otherwise
promote the proliferation of cytotoxic cells (T lym-
phocytes and NK cells), B lymphocytes and the devel-
opment of antibody-dependent cell-mediated cytotoxi-
city. Interleukin-10 plays a key role in preventing
embryo resorption by antagonising IFN γ and tumour
necrosis factor alpha (TNF α).
Progesterone is also involved in maintaining the
semi-allograft because of its local anti-inflammatory
activity; it can inhibit phagocytosis and lymphocyte
proliferation in the uterus, either directly (by blocking
CD4+ T lymphocyte activity and proliferation induced
by IL-1) or indirectly (by inducing the release of two
immunosuppressor factors by the lymphocytes). These
are T-suppressor-induced factor (TSIF) – antibodies
against which can abort a pregnancy in mice – and
progesterone-induced blocking factor (PIBF), which
blocks the lysis of embryo fibroblasts by NK cells and
inhibits mixed lymphocyte reactions by preventing
TNFα secretion by cytotoxic cells (T lymphocytes,
NK cells, etc.). Progesterone also has an immunosup-
pressive action which works in synergy with the
prostaglandins E (PGE) and inhibits T lymphocyte
proliferation.
This anti-complement activity is caused by the
embryo's expression of anti-complement molecules:
membrane complement protein (MCP, also known as
CD 46), protectin (CD 59, which stops complement
from binding to the constant region of the antibody
chain) and DAF (CD 55, which accelerates comple-
ment destruction). These molecules are expressed on
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the membranes of gametes, fertilized eggs and blasto-
cysts and thus transform any cytotoxic antibody into a
blocking antibody – a sub-class of facilitating antibod-
ies. Hence, a humorally-mediated abortion is theoreti-
cally possible if these molecules are expressed weakly,
incorrectly or not at all or are expressed at the wrong
stage or in the wrong location.
The uterine environment 
Hydrosalpynx
Analysis of the literature reveals that the hydrosalpynx
has an impact on embryo implantation. In fact, in a
personal meta-analysis of 7 studies between X and Y
featuring 2321 embryos transferred with hydrosalpynx
and 9526 without, the implantation and pregnancy
rates per cycle differed significantly according to the
presence and absence of hydrosalpinx, with implanta-
tion rates of 6.6% and 11.5%, respectively, and preg-
nancy rates of 19.7% versus 30.3%, respectively. The
physiopathology of this interaction involves an
increase in the endometrium's production of anti-
implantation cytokines (TNFα, IL-2 and IL-12) under
the effect of the chronic endometritis following on
from hydrosalpynx.
Uterine contractions 
The impact of myometrial uterine contractions (UCs)
during embryo transfer has been clearly demonstrated
by Fanchin et al. [39] via image analysis of digitized
ultrasound scans. The contractions are inversely pro-
portional to the progesterone level at the time of trans-
fer, since this hormone is known to have muscle-relax-
ant properties. When there were fewer than 3 UCs per
minute, a mean progesterone level of 111 ng/ml led to
implantation and pregnancy rates of 21% and 53%,
respectively. With more than 5 UCs per minute, the
mean progesterone level was only 68 ng/ml and
implantation and pregnancy rates of respectively 4%
and 14% were recorded. This notion again confirms
the requirement for satisfactory progesterone impreg-
nation of the uterus, in order to achieve not only ade-
quate endometrial maturation but also establishment of
the hormone's muscle-relaxant effect on the myometri-
um.
Cases of preeclampsia 
The placentas of women with preeclampsia express
lower levels of MMP-9, HLA G and α1β1 than those
of women with normal pregnancies; the integrin α6β4
level is similar and that of α5β1 is higher [40]. More-
over, neither the switch from E-cadherin to VE-cad-
herin nor VCAM-1 and PECAM-1 production occur
[41]. These phenomena attest to loss of the cytotro-
phoblasts' capacity for deep invasion. Invasive EVCTs
dedifferentiate into syncytium (giant cells) that lack
penetrating power; the increase in giant cells thus
expresses this initial impulse [42]. A related finding is
the higher frequency of preeclampsia and intrauterine
growth restriction in nulliparas (75% of cases): this
may be associated with the fact that the arteries colo-
nized during a first pregnancy can be more easily
invaded during subsequent pregnancies. The decidual
NK cells may explain why subsequent invasion is
facilitated, since they can be thought of as storing the
"endometrial memory" of paternal antibodies.
Preeclampsia was similar in nulliparas and in multi-
paras who had changed partners (3.2% and 3%,
respectively) but less frequent for multiparas with the
same partner (1.9%). A similar finding is noted in
pregnancies after oocyte or sperm donation or a long
period of barrier contraceptive use. Accordingly, we
should consider preeclampsia to be a disease of primi-
paternity rather than primigravidity.
In, the second trophoblast invasion either does not
occur or is incomplete because of the lack of intravas-
cular plugs. This translates into the persistence of uter-
ine vasoconstriction; blood intake into the intervillous
spaces is diminished and foetal growth retardation
ensues. The downstream consequence of this vasocon-
striction is hypoxia [43], with an increase in lipid per-
oxidation and in the TXA2/PGI2 ratios [44], both of
which accentuate vasoconstriction and platelet aggre-
gation. Thromboses and disseminated fibrin deposits
are usually found in the preeclampsia placenta [45].
Moreover, downstream hypoxia increases ET-1 pro-
duction and diminishes that of NO – a phenomenon
that is also related to the reduced mechanical force
exerted on the artery wall.
Preeclampsia is thus characterised by (i) an
increase in systemic vascular resistance and vascular
reactivity and (ii) a change in the distribution of pelvic
blood flow, which precedes the onset of hypertension.
All of these factors evidence the dysregulation of the
normal vasomotor factors during pregnancy. The
increase in the vasoconstrictor/vasodilator ratio is pro-
portional to the severity of the preeclampsia, and NO
metabolite levels also diminish. Rats treated with L-
NAME develop hypertension and proteinuria and the
growth of their foetuses is retarded. Hence, NO donors
may have therapeutic value because they reduce blood
pressure, inhibit platelet activation and improve uter-
ine and foetal haemodynamics [31]. 
Accordingly, it is appropriate to prescribe a preven-
tive treatment with aspirin in pregnancies where the
women have poor obstetrics histories of previous early
severe preeclampsia or severe intrauterine growth
retardation defined as <3rd percentile [46]. It appears
necessary to begin the treatment as early as possible:
from 13 weeks or even earlier (depending on the
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pathophysiologic bases explained above) when the
indication is associated with the obstetrical history.
This early prescription will have as its goal to limit,
but not to prevent, the cascade of biological events in
the mother (increase of renin, angiotensin, and aldos-
terone) that follow the increase in vascular resistance
and the obstetrical complications that can result from
it. This treatment should be continued until a term of
35 weeks. In some indications, this treatment can
begin even before conception (for autoimmune dis-
eases such as antiphospholipid syndrome), combined
with heparin or corticosteroid therapy. Although trials
have been performed with varying doses of aspirin
(from 50 to 150 mg), the optimal dose does not seem
to have been established. Nonetheless, the initial dose
usually prescribed is from 100-150 mg per day. 
Lastly, chronic hypoxia (resulting from a placenta-
tion defect) can induce the transcription of certain
genes, including that of ET-1 (a vasoconstrictor),
angiotensin conversion enzyme (a hypertensive agent),
plasminogen activator [47] (stimulating formation of
active TGF β, which inhibits the EVCT invasion) and
cyclooxygenase-1 (COX-1, an enzyme involved in
prostaglandin production). 
These observations and the notion of a sequence of
preeclampsia/early repeated abortions in the same
patients suggest that these two diseases may be on a
continuum.
During preeclampsia, trophoblast expression of
HLA G falls at the mRNA level, in proportion to the
reduction in the number of trophoblast cells observed
in this disease.
As normal pregnancy progresses, macrophage and
T lymphocyte counts remain constant, whereas the
number of LGL falls. The LGLs have a particular NK
phenotype and play a role in graft immunity. Further-
more, HLA G can inhibit LGL NK activity. One role of
these uterine myeloid cells is to produce cytokines. A
successful pregnancy requires a dominant Th2 system
(humoral-mediated immunity by cytokines). During
preeclampsia, this relationship is inversed (Th1>Th2),
thereby increasing the rate of destruction of tro-
phoblast cells (Th1 = cell-mediated immunity). In
addition, anomalies in PGE2 and TGFβ production
have been observed during preeclampsia.
Hence, preeclampsia is characterised by general-
ized endothelial cell dysfunction and is linked to sev-
eral factors: fatty acids, lipoproteins, lipid peroxide,
TNFα, fibronectin decay products and syncytiotro-
phoblast microvillous fragments. All these various fac-
tors are generated by a generalized, intravascular,
inflammatory response which is present during preg-
nancy but exacerbated in preeclampsia [48]. During
inflammation, levels of leukocyte adhesion proteins in
the vascular system rise, due to premature stimulation
by first thrombin and histamine and then, in the hours
that follow, by IL1 or TNFα. Vascular permeability then
increases the cellular chemotaxis with phagocytosis. 
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